Correlation Between Virbac SA and Innate Pharma

Can any of the company-specific risk be diversified away by investing in both Virbac SA and Innate Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virbac SA and Innate Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virbac SA and Innate Pharma, you can compare the effects of market volatilities on Virbac SA and Innate Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virbac SA with a short position of Innate Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virbac SA and Innate Pharma.

Diversification Opportunities for Virbac SA and Innate Pharma

-0.36

Correlation Coefficient

Virbac SA  Innate Pharma

Very good diversification

The 3 months correlation between Virbac and Innate is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding Virbac SA and Innate Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innate Pharma and Virbac SA is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virbac SA are associated (or correlated) with Innate Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innate Pharma has no effect on the direction of Virbac SA i.e., Virbac SA and Innate Pharma go up and down completely randomly.

Pair Corralation between Virbac SA and Innate Pharma

Assuming the 90 days trading horizon Virbac SA is expected to under-perform the Innate Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Virbac SA is 1.49 times less risky than Innate Pharma. The stock trades about -0.01 of its potential returns per unit of risk. The Innate Pharma is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  193.00  in Innate Pharma on December 22, 2024 and sell it today you would lose (5.00) from holding Innate Pharma or give up 2.59% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.41%
Values	Daily Returns

Virbac SA  vs.  Innate Pharma

Virbac SA

Risk-Adjusted Performance

Very Weak

Over the last 90 days Virbac SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Virbac SA is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Innate Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical indicators, Innate Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Virbac SA and Innate Pharma

The main advantage of trading using opposite Virbac SA and Innate Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virbac SA position performs unexpectedly, Innate Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innate Pharma will offset losses from the drop in Innate Pharma's long position.

The idea behind Virbac SA and Innate Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.